Skip to main content
. 2024 Sep 15;14(9):4337–4352. doi: 10.62347/KCPN6689

Figure 6.

Figure 6

NR4A2 knockout inhibits tumor growth in vivo. (A) Mice were injected with wild-type and CRISPR/Cas9-derived NR4A2 knockout MiaPaCa2 cells and tumor growth was monitored for 6 weeks. Images represents the tumor size at the end of the experiment. (B) Tumor growth associated with wild-type and NR4A2 knockout MiaPaCa2 cells as xenografts and (C) tumor volumes determined 6 weeks after initial injection. (D) Mice with tumors were examined for tumor free survival until the tumors were palpable. (E) Western blot analysis of HuR expression in tumors derived from wild-type (NR4A2+/+) and knockout (NR4A2-/-) MiaPaCa2 cells as xenografts. (F) Relative mRNA levels of NR4A2, HuR and IDH1 normalized to mRNA levels of 18S and (G) α-ketoglutarate levels in tumors derived from wild-type and NR4A2 knockout MiaPaCa2 cells. (H) Immunohistochemistry images and Percentage analysis of Ki-67 in 10% neutral buffer formalin fixed and paraffin embedded (FFPE) tissue sections of tumors derived from wild-type and NR4A2 knockout MiaPaCa2 cell xenografts. Quantitated results are means ± SE for at least 3 replicate determinations; significance, **P<0.01, ***P<0.001.